osimertinib
astrazeneca
['osimertinib']
 this flaw would have been easy to fix. investigators could have demanded access to osimertinib from sponsor for control arm progression or just refused to open study. but this will never happen as long as studies like this are plenary at asco and published in nejm.
Hematologist/Bone marrow transplanter at UCSD/educator - loves teaching all of Twitter medicine, husband+father/Guitar 🎸/Nirvana best band ever!/Loves tacos